AR075049A1 - Compuestos antidiabeticos que contienen pentafluorsulfolano - Google Patents
Compuestos antidiabeticos que contienen pentafluorsulfolanoInfo
- Publication number
- AR075049A1 AR075049A1 ARP100100144A ARP100100144A AR075049A1 AR 075049 A1 AR075049 A1 AR 075049A1 AR P100100144 A ARP100100144 A AR P100100144A AR P100100144 A ARP100100144 A AR P100100144A AR 075049 A1 AR075049 A1 AR 075049A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- cycloalkyl
- cycloalkylalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14683309P | 2009-01-23 | 2009-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075049A1 true AR075049A1 (es) | 2011-03-02 |
Family
ID=42084439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100144A AR075049A1 (es) | 2009-01-23 | 2010-01-22 | Compuestos antidiabeticos que contienen pentafluorsulfolano |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110313008A1 (de) |
| EP (1) | EP2389369A1 (de) |
| JP (1) | JP2012515779A (de) |
| AR (1) | AR075049A1 (de) |
| AU (1) | AU2010206783A1 (de) |
| CA (1) | CA2749663A1 (de) |
| TW (1) | TW201040170A (de) |
| WO (1) | WO2010085522A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2389368B1 (de) | 2009-01-23 | 2015-06-17 | Merck Sharp & Dohme Corp. | Verbrückte und kondensierte antidiabetische verbindungen |
| EP2393810A1 (de) | 2009-02-05 | 2011-12-14 | Schering Corporation | Phthalazinhaltige antidiabetische verbindungen |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| BR112015002080A2 (pt) | 2012-08-02 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença |
| EP2958562A4 (de) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EA201690888A1 (ru) | 2013-11-14 | 2016-10-31 | Кадила Хелзкэр Лимитед | Новые гетероциклические соединения |
| WO2015073342A1 (en) | 2013-11-15 | 2015-05-21 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3076959B1 (de) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetische bicyclische verbindungen |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3177285B1 (de) | 2014-08-08 | 2020-09-23 | Merck Sharp & Dohme Corp. | [5,6]-kondensierte bicyclische antidiabetische verbindungen |
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
| EP3551176A4 (de) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetische heterocyclische verbindungen |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| WO2019099315A1 (en) | 2017-11-16 | 2019-05-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| PL3752501T3 (pl) | 2018-02-13 | 2023-08-21 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
| EP3781556A1 (de) | 2018-04-19 | 2021-02-24 | Gilead Sciences, Inc. | Pd-1/pd-l1-inhibitoren |
| PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CA3121199A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| EP4041722A4 (de) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | Gpr119-agonisten |
| KR20230012597A (ko) | 2020-05-19 | 2023-01-26 | 칼리오페, 인크. | Ampk 활성화제 |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759493B2 (en) * | 2005-01-31 | 2010-07-20 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
-
2010
- 2010-01-21 EP EP10704242A patent/EP2389369A1/de not_active Withdrawn
- 2010-01-21 CA CA2749663A patent/CA2749663A1/en not_active Abandoned
- 2010-01-21 AU AU2010206783A patent/AU2010206783A1/en not_active Abandoned
- 2010-01-21 WO PCT/US2010/021577 patent/WO2010085522A1/en active Application Filing
- 2010-01-21 JP JP2011548084A patent/JP2012515779A/ja not_active Withdrawn
- 2010-01-21 US US13/145,025 patent/US20110313008A1/en not_active Abandoned
- 2010-01-22 TW TW099101801A patent/TW201040170A/zh unknown
- 2010-01-22 AR ARP100100144A patent/AR075049A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010085522A1 (en) | 2010-07-29 |
| EP2389369A1 (de) | 2011-11-30 |
| JP2012515779A (ja) | 2012-07-12 |
| AU2010206783A1 (en) | 2011-07-28 |
| US20110313008A1 (en) | 2011-12-22 |
| CA2749663A1 (en) | 2010-07-29 |
| TW201040170A (en) | 2010-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075049A1 (es) | Compuestos antidiabeticos que contienen pentafluorsulfolano | |
| AR074965A1 (es) | Compuestos antidiabeticos heterociclicos puenteados y fusionados | |
| AR075051A1 (es) | Compuestos antidiabeticos que contienen ftalazina | |
| AR075150A1 (es) | Compuestos antidiabeticos en puente y fusionados | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| AR059021A1 (es) | Moduladores de receptores cannabinoides | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| AR074354A1 (es) | Alquilciclohexileteres de dihidrotetraazabenzoazulenos, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR085149A1 (es) | Moduladores del receptor de glucagon | |
| AR059056A1 (es) | Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia | |
| PE20090217A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR062050A1 (es) | Derivados de amina utiles como agentes anti-cancerigenos | |
| AR080083A1 (es) | Moduladores de gamma-secretasa | |
| PE20091096A1 (es) | Compuestos organicos | |
| AR069804A1 (es) | Agonistas del receptor glucocorticoide c20- c21 sustituido | |
| AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AR066043A1 (es) | Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1) | |
| AR070437A1 (es) | Moduladores de beta - amiloide | |
| AR092684A1 (es) | Compuestos de sulfonamida sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |